Dipeptides as effective prodrugs of the unnatural amino acid (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740), a selective group II metabotropic glutamate receptor agonist

Journal of Medicinal Chemistry

Volumn 48, Issue 16, 2005, Pages 5305-5320

  Bueno, Ana Belén ^a   Collado, Iván ^a   De Dios, Alfonso ^a   Domínguez, Carmen ^a   Martín, José Alfredo ^a   Martín, Luisa M ^a   Martínez Grau, María Angeles ^a   Montero, Carlos ^a   Pedregal, Concepción ^a   Catlow, John ^b   Coffey, D Scott ^b   Clay, Michael P ^b   Dantzig, Anne H ^b   Lindstrom, Terry ^b   Monn, James A ^b   Jiang, Haiyan ^b   Schoepp, Darryle D ^b   Stratford, Robert E ^b   Tabas, Linda B ^b   Tizzano, Joseph P ^b,d   Wright, Rebecca A ^b   Herin, Marc F ^c   more..

^a ELI LILLY AND COMPANY   (Spain)

^b ELI LILLY AND COMPANY   (United States)

^c Eli Lilly Benelux   (Belgium)

^d DOV Pharmaceutical Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [(2' AMINO)PROPIONYL]AMINOBICYCLO[3.1.0]HEXANE 2,6 DICARBOXYLIC ACID; DIAZEPAM; DIPEPTIDE DERIVATIVE; EGLUMETAD; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; PEPTIDE TRANSPORTER 1; TRIPEPTIDE; UNCLASSIFIED DRUG;

ACTIVE TRANSPORT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; CONTROLLED STUDY; DEPROTECTION REACTION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG TARGETING; FEAR; HUMAN; HUMAN CELL; HUMAN TISSUE; INTESTINE ABSORPTION; MALE; NONHUMAN; RAT; SPECIES IDENTIFICATION; STARTLE REFLEX;

EID: 23444432215     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050235r     Document Type: Article

References (35)

1. (a) Collingridge, G. L.; Lester, R. A. Excitatory amino acid receptor in the vertebrate central nervous system. Pharmacol. Rev. 1989, 40, 143-210.
2. (b) Cunningham, M. D.; Ferkany, J. W.; Enna, S. J. Excitatory amino acid receptors: A gallery of new targets for pharmocological intervention. Life Sci. 1994,54, 135-148.
3. (a) Hollmann, M.; Heinemann, S. Cloned glutamate receptors. Annu. Rev. Neurosci. 1994, 17, 31-108.
4. (b) Nakanishi, S.; Masu, M. Molecular diversity and functions of glutamate receptors. Annu. Rev. Biophys. Biomol. Struct. 1994, 23, 319-348.
5. Monn, J. A.; Valli, M. J.; Massey, S. M.; Wright, R. A.; Salhoff, C. R.; Johnson, B. G.; Howe, T.; Alt, C. A.; Rhodes, G. A.; Robey, R. L.; Griffey, K. R.; Tizzano, J. P.; Kallman, M. J.; Helton, D. R.; Schoepp, D. D. Design, synthesis and pharmacological characterization of (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): a potent, selective and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties. J. Med. Chem. 1997, 40, 528-537.
6. Schoepp, D. D.; Monn, J. A.; Marek, G. J.; Aghajanian, G.; Moghaddam, B. LY354740: A systemically active mGlu2/3 receptor agonist. CNS Drug Rev. 1999, 5 (1), 1-12.
7. Shekar, A.; Keim, S. R. LY354740, a potent group II metabotropic glutamate receptor agonist prevents lactate-induced panic-like response in panic-prone rats. Neuropharmacology 2000, 39, 1139-1146.
8. Johnson, J. T.; Mattiuz, E. L.; Chay, S. H.; Herman, J. L.; Wheeler, W. J.; Kassahun, K.; Swanson, S. P.; Phillips, D. L. The disposition, metabolism, and pharmacokinetics of a selective metabotropic glutamate receptor agonist in rats and dogs. Drug Metab. Dispos. 2002, 30, 27-33.
9. For brain levels of LY354740 after systemic administration, see the following. Battaglia, G.; Monn, J. A.; Schoepp, D. D. In vivo inhibition of veratridine-evoked release of striatal excitatory amino acids by the group II metabotropic glutamate receptor agonist LY354740 in rats. Neurosci. Lett. 1997, 229, 161-164.
10. Yang, Ch. Y.; Dantzig, A. H.; Pidgeon, Ch. Intestinal peptide transport systems and oral drug availability. Pharm. Res. 1999, 16 (9), 1331-1343.
11. Ganapathy, V.; Brandsch, M.; Leibach, F. H. Intestinal Transport of Amino Acids and Peptides. In Physiology of the Gastrointestinal Tract; Johnson, L. R., Ed.; Raven Press: New York, 1994; pp 1773-1794.
12. Mathews, D. M.; Adibi, S. A. Peptide absorption. Gastroenterology 1976, 71, 151-161.
13. Ganapathy, V.; Leibach, F. H. Is intestinal peptide transport energized by a proton gradient? Am. J. Physiol. 1985, 249, G153-G160.
14. Dantzig, A. H. Oral absorption of β-lactams by intestinal peptide transport proteins. Adv. Drug Delivery Rev. 1998, 23, 63-76.
15. Inui, K.; Yamamoto, M.; Saito, H. Transepithelial transport of oral cephalosporins by monolayers of intestinal epithelial cell line caco-2: specific transport systems in apical and basolateral membranes. J. Pharmacol. Exp. Ther. 1992, 261, 195-201.
16. Kim, J. S.; Oberle, R. L.; Krummel, D. A.; Dressman, J. B.; Fleisher, D. Absorption of ACE inhibitors from small intestine and colon. J. Pharm. Sci. 1994, 83, 1350-1356.
17. Hashimoto, N.; Fujioka, T.; Toyoda, T.; Muranushi, N.; Hirano, K. Renin inhibitor: transport mechanism in rat small intestinal brush-border membrane vesicles. Pharm. Res. 1994, 11, 1448-1451.
18. Temple, C. S.; Steward, A. K.; Meredith, D.; Lister, N. A.; Morgan, K. M.; Collier, I. D.; Vaughan-Jones, R. D.; Boyd, C. A. R.; Bailey, P. D.; Bronk, J. R. Peptide mimics as substrates for the intestinal peptide transporter. J. Biol. Chem. 1998, 273, 20-22.
19. Döring, F.; Will, J.; Amasheh, S.; Clauss, W.; Ahlbrecht, H.; Daniel, H. Minimal molecular determinants of substrates for recognition by the intestinal peptide transporter. J. Biol. Chem. 1998, 273, 23211-23218.
20. Han, H. K.; deVrueh, R. A.; Rhie, J. K.; Covitz, K. Y.; Smith, P. L.; Lee, C. P.; Oh, D. M.; Sadee, W.; Amidon, G. L. 5′-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm. Res. 1998, 15, 1154-1159.
21. Hu, M.; Subramanian, P.; Mosberg, H. I.; Amidon, G. L. Use of peptide carrier system to improve the intestinal absorption of L-alpha-methyldopa: carrier kinetics, intestinal permeabilities and in vitro hydrolysis of dipeptidyl derivatives of L-alpha-methyldopa. Pharm. Res. 1989, 6, 66-70.
22. Wang, H. P.; Lu, H. H.; Lee, J. S.; Cheng, C. Y.; Mah, J. R.; Ku, C. Y.; Hsu, W.; Yen, C. F.; Lin, C. J.; Kuo, H. S. Intestinal absorption studies on peptide mimetic alpha-methyldopa prodrugs. J. Pharm. Pharmacol. 1996, 48, 270-276.
23. This reaction led to a 10:1 mixture of the C-6 allylated and C-2 allylated regioisomers.
24. Wakamiya, T.; Oda, Y.; Fujita, H.; Shiba, T. Synthesis and stereochemistry of carnosadine, a new cyclopropyl amino acid from red alga grateloupia carnosa. Tetrahedron Lett. 1986, 27 (19), 2143-2144.
25. Hoffmann, M. G.; Zeiss, H.-J. A novel and convenient route to L-homoserine lactones and L-phosphinothricin from L-aspartic acid. Tetrahedron Lett. 1992, 33 (19), 2669-2672.
26. Gu, Z.-Q.; Hesson, D. P.; Pelletier, J. C.; Maccecchini, M.-L.; Zhou, L.-M.; Skolnick, P. Synthesis, resolution, and biological evaluation of the four stereoisomers of 4-methylglutamic acid: Selective probes of kainate receptors, J. Med. Chem. 1995, 38 (14), 2518-2520.
27. The one exception was the N-2 proline peptide 12i. Other N-terminal proline dipeptides, like Pro-Gly, are poor substrates for the peptide transporter in Caco-2 cells. See the following: Dantzig, A. H.; Bergin, L. Biochim. Biophys. Acta 1990, 1027, 211-217.
28. 3H]LY341495, a highly potent, selective and novel radioligand for labeling group II metabotropic glutamate receptors. Bioorg. Med. Chem. Lett. 1998, 8, 1919-1922.
29. 3H]-LY341495 as a novel rapid filtration antagonist radioligand for group II metabotropic glutamate receptors: Characterization of binding to membranes of mGlu receptor subtype expressing cells. Neuropharmacology 1999, 38, 1519-1529.
30. (a) Helton, D. R.; Tizzano, J. P.; Monn, J. A.; Schoepp, D. D.; Kallman, M. J. Anxiolytic and side-effect profile of LY354740: A potent, highly selective, orally active agonist for group II metabotropic glutamate receptors. J. Pharmacol. Exp. Ther. 1998, 284, 651-660.
31. (b) Tizzano, J. P.; Grifffey, K. I.; Ornstein, P. L.; Monn, J. A.; Schoepp, D. D. Actions of mGlu receptor agonists on fear-conditioning versus fear-expression in rats. Neuropharmacology 1999, 38, A45 (no. 144).
32. Kingston, A. E.; Ornstein, P. L.; Wright, R. A.; Johnson, B. G.; Mayne, N. G.; Burnett, J. P.; Belagaje, R.; Wu, S.; Schoepp, D. D. LY341495 is a nanomolar potent and selective antagonist for group II metabotropic glutamate receptors. Neuropharmacology 1998, 37, 1-12.
33. The good affinity of hPepT1 for the C-2 dipeptides and the high concentration of prodrug in plasma following oral administration of the indicated C-2 dipeptides suggest that these prodrugs are absorbed but not readily hydrolyzed to the parent whereas the N peptides apparently absorbed well and hydrolyzed.
34. Novachek, K. A.; Meyers, A. I. A convenient procedure for the reduction of S-(+)-silyl serine methyl ester to chiral serinol derivatives. Tetrahedron Lett. 1996, 37 (11), 1743-1746.
35. Jacobsen, E.; Mitchell, M. A.; Hendges, S. K.; Belonga, K. L.; Skaletzky, L. L.; Stelzer, L. S.; Lindberg, T. J.; Fritzen, E. L.; Schostarez, H. J.; O'Sullivan, T. J.; Maggiora, L. L.; Stuchly, C. W.; Laborde, A. L.; Kubicek, M. F.; Poorman, R. A.; Beck, J. M.; Miller, H. R.; Petzold, G. L.; Scott, P. S.; Truesdell, S. E.; Wallace, T. L.; Wilks, J. W.; Fisher, C.; Goodman, L. V.; Kaytes, P. S.; Ledbetter, S. R.; Powers, E. A.; Vogeli, G.; Mott, J. E.; Trepod, C. M.; Staples, D. J.; Baldwin, E. T.; Finzel, B. C. Synthesis of a series of stromelysin-selective thiadiazole urea matrix metalloproteinase inhibitors. J. Med. Chem. 1999, 42 (9), 1525-1536.